We are committed to increasing the accessibility of genomic testing to ensure more women receive the treatment that’s right for their breast cancer. Thanks to key collaborations with insurance carriers, the Agendia tests are covered by most healthcare plans in the U.S. and around the world. They are available to any patient who meets the eligibility criteria. MammaPrint is FDA-cleared for women of all ages. MammaPrint is also available via next generation sequencing on Illumina MiSeq platform. This approach has been CE marked allowing use in the European Union.